European Medicines Agency (EMA) receives application for marketing authorisation of Dexamethasone Taw Injection for COVID-19

EMA has started evaluating an application for Dexamethasone Taw for treating hospitalised adult patients with COVID-19. Before receiving this application, the CHMP had started reviewing the RECOVERY trial and outcome of this review will be considered in evaluation of this product


European Medicines Agency